September 2026In the ordinary case, yes. If you hold the patent inside a real trade or business, the annuity you pay to keep it alive is a business cost and it comes off your taxable income. That is where almost every page on this question stops, and it is the least useful part of the answer.
Deductible is a yes or no word. The tax code does not deal in yes or no here, it deals in timing. Whether you take the money this year or spread it over five, fifteen or twenty is decided by facts most owners never think of as tax facts: whether you built the patent or bought it, which country the money was spent in, and whether you are about to keep the asset or get rid of it.
Here is what the sources actually say, including the place where two of the most-read pages on this topic flatly contradict each other.
To be deducted as a business expense in the United States, a cost has to clear two tests: it must be an ordinary and necessary expense rather than a capital expenditure, and it must be paid or incurred in carrying on a trade or business. A renewal fee on a patent your company is using, licensing or actively trying to sell clears both without much argument.
In practice most owners never even reach the debate, because annuity fees are usually expensed rather than capitalised on materiality grounds, being small and recurring, though that changes for a company holding many commercialised patents where the annuities add up to something material. Small numbers get expensed. Large ones invite the harder question.
The words matter, because the tax treatment follows the legal act, not the invoice.
United States maintenance fees are post-grant. They are required for utility and reissue utility patents, not for design or plant patents, and paid in windows at 3 to 3.5, 7 to 7.5 and 11 to 11.5 years after issue, with six month grace periods carrying a surcharge and reductions of 60 percent for small entities and 80 percent for micro entities. European renewal fees are annual and start while the application is still pending. For the amounts themselves, we have set out what the fees actually cost, in the US and at the EPO rather than repeat the tables here.
Hold on to one distinction: a US maintenance fee can only ever be paid on a patent that has already been granted.
Search this question and you will be handed two incompatible answers by two confident pages.
One well-ranked accounting guide lists maintenance fees paid to the patent office among the costs treated as research and experimental expenditures, capitalised and recovered through amortisation reported on Form 4562 Part VI. A specialist R&D tax firm says the opposite: routine maintenance fees paid to keep an existing granted patent in force are not costs of making and perfecting an invention, they are administrative costs of maintaining an asset that already has commercial status, and they sit outside the section 174 base and outside the section 41 credit base.
Both cannot be right, and the statutory language points one way. The IRS defines the category as including the cost of obtaining a patent, such as attorneys' fees expended in making and perfecting a patent application. Making and perfecting an application is a pre-grant act. A fee whose only function is to stop an already granted patent from lapsing is not that act.
We are not your accountant and this is not tax advice. But if you take one question from this article into your next call with them, take this one: which section are you applying to a post-grant maintenance fee, and why. The answer changes whether you deduct it this year or wait five.
The costs of securing your own invention run through the research and experimental rules, and those rules have moved twice in four years. The 2017 Tax Cuts and Jobs Act removed the option to deduct immediately and forced capitalisation with five year amortisation for tax years 2022 through 2024, then the One Big Beautiful Bill Act of 2025 enacted section 174A to restore immediate deductibility for domestic patent perfection costs while keeping the fifteen year treatment for foreign-incurred spend. If your accountant is working from a 2023 memo, they are working from a rule that no longer applies.
Completely different regime. Capitalised costs of section 197 intangibles acquired after 10 August 1993 must generally be amortised over fifteen years when held in connection with a trade or business. Fifteen years, straight line, whether or not the patent has fifteen years of term left. For a small company that just bought a patent with eight years to run, that steady deduction is a real cash flow consideration rather than a formality.
The geography of the spend is its own fork. Foreign research or experimental expenditures must be charged to capital account and amortised over fifteen years, against five for domestic. A US company prosecuting the same family through European counsel can therefore be running two recovery clocks on one invention.
Cross the Atlantic and the logic inverts. German tax accounting refuses to let you capitalise a patent you created yourself: self-created intangible fixed assets may not be shown in the tax balance sheet under section 5 Abs. 2 EStG, so both the development expenditure and the costs of securing legal protection are recorded as expense. Where US rules push a self-developed patent toward the balance sheet, German rules forbid it.
Buy the patent instead, or have a third party develop it under a Werkvertrag, and Germany flips to the mirror image: the acquisition cost is capitalised as an intangible asset and written down over twenty years from purchase or completion, and the closing advice from German tax practitioners is to involve a Steuerberater before assuming which case you are in.
For a spinout filing in both jurisdictions this is not trivia. The same self-created family can be an immediately deductible expense in Germany and a capitalised asset in the United States, on the same set of invoices. And note what the exclusion above means for anyone hoping to route patent costs into an R&D incentive: patent procurement is legal work, not experimentation, which is why it falls outside the credit base. What German R&D relief does reach is a separate question, and we have covered Germany's separate research allowance for R&D work elsewhere.
Every renewal notice is a decision point disguised as a bill. The tax consequence of that decision dwarfs the deduction on the fee itself.
There is a loss available. The regulations allow a deduction for a loss arising from the sudden termination of the usefulness of nondepreciable property that is permanently discarded from the business, taken in the year the loss is actually sustained, which is not necessarily the year of the overt act of abandonment.
Two things spoil it. First, the evidentiary bar is higher than not paying an invoice. You have to show both an intention to abandon and an affirmative act of abandonment, and mere non-use of an asset is not sufficient, nor are internal communications inside your own organisation; a deduction is refused outright where you are holding the property in the hope of future value. Quietly missing a payment while telling your board the family might still be worth something is close to the worst version of this.
Second, and this is the one that surprises people, the loss is measured on adjusted basis. An owner who already expensed the development costs may have almost nothing left to write off. There is also a trap in the statute for foreign spend: disposal, retirement or abandonment brings no acceleration at all, and the fifteen year amortisation simply continues as if nothing happened.
The honest summary is that letting a patent lapse is rarely the tax win people imagine. It is usually just the end of the spending.
Now the treatment gets genuinely favourable, for one specific type of owner. A transfer of all substantial rights to a patent by a holder is treated as the sale or exchange of a capital asset held for more than one year, regardless of whether the payments are made periodically over the transferee's use of the patent or contingent on its productivity, use or disposition. Read that twice. Payments that look exactly like royalties are still capital gain, if the section applies.
The limits are strict. A transfer by a person other than a holder, or by a holder to a related person, is outside the section entirely, and payments made by the transferee are purchase price rather than royalties. Holder means an individual whose own efforts created the property. A corporate patent owner does not get this.
So the asymmetry at the deadline looks like this. Deducting the annuity returns you a fraction of a fee at ordinary rates. Abandoning gives you a loss that may be worth nothing. Selling can change the tax character of the entire asset. The annuity is the smallest number on the page and it is the only one most owners think about.
One practical consequence follows from all of the above. A brokered patent sale runs on months, not weeks, and a patent sitting just in front of a large maintenance payment is a harder sell than one just past it, because the buyer inherits that bill along with the asset. Deciding to monetise in the last fortnight before a deadline means negotiating from the weakest position available.
It is also worth checking who carries the risk in whatever process you run. Our own brokerage is success-based: the seller pays commission on completion, with a minimum fee of EUR 5,000 per completed transaction, and no sale means no fee. If you want the pricing question first, start with what a buyer would actually pay and then the best way to sell a patent. If you are earlier in the cycle and still weighing whether to file at all, look at what it cost to get the patent in the first place.
Six questions, each one a real fork above rather than a formality.
This article is general information about how these rules are described by the sources cited, not tax advice, and none of it is a substitute for an adviser who has seen your file.
Can an individual inventor deduct patent renewal fees? Only if there is a trade or business behind the patent. The deduction requires both an ordinary and necessary expense and a cost paid in carrying on a trade or business, with a separate provision covering expenses for the production of income. An inventor holding a granted patent with no commercial activity around it is the case most likely to fail that test.
Do patent maintenance fees qualify for the R&D tax credit? No. Patent procurement costs can fall under the research and experimental rules but not under the credit, because they resolve legal rather than technological uncertainty, and routine maintenance on a granted patent is treated as administrative overhead rather than research at all.
Do I get a tax deduction if I let my patent lapse? Possibly, as an abandonment loss, but two conditions bite. The loss equals your adjusted basis, which may be near zero if the costs were already expensed, and you need a documented intention plus an affirmative act. Simply stopping payment may not be enough on its own.
Are patent litigation costs deductible? Fees to defend an existing patent against infringement are generally deductible as ordinary and necessary business expenses in the year incurred, a treatment the Federal Circuit affirmed for Hatch-Waxman defence costs in the Actavis decision of March 2025. Costs incurred to defend or perfect title to the patent are treated differently and capitalised.
Are patent renewal fees deductible in Germany? For a self-created patent, yes and immediately, because German tax law bars capitalising self-created intangible fixed assets, so the costs of securing legal protection are booked as expense. A purchased patent is the opposite case, capitalised and written down over twenty years.
We use essential cookies to operate this website and, with your consent, optional cookies to understand site usage. You can accept or decline non-essential cookies at any time. See our Impressum for our contact and legal details.